Trial Profile
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Olaparib (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 01 Sep 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2024.
- 01 Sep 2023 Planned primary completion date changed from 31 Aug 2023 to 31 Aug 2024.
- 19 Apr 2023 Results assessing the efficacy of the PARPi olaparib as monotherapy vs. in combination with PD-L1 inhibitor atezolizumab in patients with BRCAmt advanced breast cancer presented at the 114th Annual Meeting of the American Association for Cancer Research